NICE approves alemtuzumab for multiple sclerosis

Genzyme's immunosuppressant alemtuzumab (Lemtrada) has been given the green light for use on the NHS in adults with active relapsing-remitting multiple sclerosis.

by
Alemtuzumab (Lemtrada) binds to the CD52 surface antigen of certain T-cells, causing both antibody-dependent and complement-mediated cell lysis | SCIENCE PHOTO LIBRARY
Alemtuzumab (Lemtrada) binds to the CD52 surface antigen of certain T-cells, causing both antibody-dependent and complement-mediated cell lysis | SCIENCE PHOTO LIBRARY

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package